Theodore E Spiro
Overview
Explore the profile of Theodore E Spiro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
846
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Spyropoulos A, Raskob G, Spiro T, Lu W, De Sanctis Y, Albanese J, et al.
TH Open
. 2022 Oct;
6(4):e304-e308.
PMID: 36299620
This post hoc subgroup analysis examined efficacy and safety outcomes with extended thromboprophylaxis rivaroxaban compared with in-hospital enoxaparin in 2,078 patients from the MAGELLAN study who had a hospitalization for...
2.
Spyropoulos A, Goldin M, Ageno W, Albers G, Elliott C, Hiatt W, et al.
TH Open
. 2022 Sep;
6(3):e177-e183.
PMID: 36046208
The MARINER trial evaluated whether postdischarge thromboprophylaxis with rivaroxaban could reduce the primary outcome of symptomatic venous thromboembolism (VTE) or VTE-related death in acutely ill medical patients at risk for...
3.
Spyropoulos A, Raskob G, Cohen A, Ageno W, Weitz J, Spiro T, et al.
Circulation
. 2022 Apr;
145(19):1471-1479.
PMID: 35389229
Background: Extended thromboprophylaxis has not been widely implemented in acutely ill medical patients because of bleeding concerns. The MAGELLAN (Multicenter, Randomized, Parallel Group Efficacy and Safety Study for the Prevention...
4.
Raskob G, Spyropoulos A, Spiro T, Lu W, Yuan Z, Levitan B, et al.
J Am Heart Assoc
. 2021 Nov;
10(22):e021579.
PMID: 34755519
Background Thromboprophylaxis extended after hospital discharge in medically ill patients currently is not recommended by practice guidelines because of uncertainty about the benefit for preventing major or fatal thromboembolic events,...
5.
Raskob G, Spyropoulos A, Cohen A, Weitz J, Ageno W, De Sanctis Y, et al.
J Am Heart Assoc
. 2021 Feb;
10(5):e019459.
PMID: 33586478
Background Asymptomatic proximal deep vein thrombosis (DVT) is an end point frequently used to evaluate the efficacy of anticoagulant thromboprophylaxis in medical patients. Recently, the clinical relevance of asymptomatic DVT...
6.
Spyropoulos A, Ageno W, Albers G, Elliott C, Halperin J, Hiatt W, et al.
J Am Coll Cardiol
. 2020 Jun;
75(25):3140-3147.
PMID: 32586587
Background: Hospitalized acutely ill medical patients are at risk for fatal and major thromboembolic events. Whether use of extended-duration primary thromboprophylaxis can prevent such events is unknown. Objectives: The purpose...
7.
Solms A, Willmann S, Reinecke I, Spiro T, Peters G, Weitz J, et al.
J Thromb Thrombolysis
. 2020 Apr;
50(1):1-11.
PMID: 32323191
Anticoagulant plasma concentrations and patient characteristics might affect the benefit-risk balance of therapy. This study assessed the impact of model-predicted rivaroxaban exposure and patient characteristics on outcomes in patients receiving...
8.
Reinecke I, Solms A, Willmann S, Spiro T, Peters G, Weitz J, et al.
J Thromb Thrombolysis
. 2020 Apr;
50(1):12-19.
PMID: 32323190
Anticoagulant plasma concentrations and patient characteristics might affect the benefit-risk balance of therapy. The study objective was to assess the impact of model-predicted rivaroxaban exposure and patient characteristics on outcomes...
9.
Spyropoulos A, Lipardi C, Xu J, Peluso C, Spiro T, De Sanctis Y, et al.
TH Open
. 2020 Mar;
4(1):e59-e65.
PMID: 32190813
An individualized approach to identify acutely ill medical patients at increased risk of venous thromboembolism (VTE) and a low risk of bleeding to optimize the benefit and risk of extended...
10.
Cunningham J, Ferreira J, Deng H, Anker S, Byra W, Cleland J, et al.
JACC Heart Fail
. 2020 Mar;
8(5):359-368.
PMID: 32171760
Objectives: This study investigated the effects of a mid-trial protocol amendment requiring elevated natriuretic peptides for inclusion in the COMMANDER-HF (A Study to Assess the Effectiveness and Safety of Rivaroxaban...